Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

van Leeuwen, Remko, Katlama, Christine, Murphy, Robert L, Squires, Kathleen, Gatell, José, Horban, Andrej, Clotet, Bonaventura, Staszewski, Shlomo, van Eeden, Arne, Clumeck, Nathan, Moroni, Mauro, Pavia, Andrew T, Schmidt, Reinhold E, Gonzalez-Lahoz, Juan, Montaner, Julio, Antunes, Francisco, Gulick, Robert, Bánhegyi, Dénes, van der Valk, Marc, Reiss, Peter, van Weert, Liesbeth, van Leth, Frank, Johnson, Victoria A, Sommadossi, Jean-Pierre, Lange, Joep MA · 2003 · AIDS

Abstract

OBJECTIVE: To compare one protease inhibitor (PI)-based and two PI-sparing antiretroviral therapy regimens. METHODS: International, open label, randomized study of antiretroviral drug-naive patients, with CD4 lymphocyte counts >/= 200 x 106 cells/l and plasma HIV-1 RNA levels > 500 copies/ml. Treatment assignment to stavudine and didanosine plus indinavir or nevirapine or lamivudine. Primary study endpoint was the percentage of patients with plasma HIV-1 RNA levels < 500 copies/ml after 48 weeks in the intention-to-treat analysis (ITT). RESULTS: In total, 298 patients were enrolled. After 48 weeks, the percentage of patients in the indinavir, nevirapine and lamivudine arms with HIV-1 RNA < 500 copies/ml was 57.0%, 58.4% and 58.7%, respectively, in an ITT analysis. After 96 weeks of follow-up, these percentages were 50.0%, 59.6% and 45.0%, respectively. The percentage of patients with HIV-1 RNA < 50 copies/ml was significantly less for those allocated to lamivudine in an on-treatment analysis after 48 and 96 weeks of follow-up. Patients in the nevirapine arm experienced a smaller increase in the absolute number of CD4 T lymphocytes. There were no significant differences in the incidence of serious adverse events. CONCLUSIONS: A comparable virological response can be achieved with first-line PI-base and PI-sparing regimens. The triple nucleoside regimen utilized may be less likely to result in viral suppression to < 50 copies/ml, while the nevirapine-based regimen is associated with a lower increase in CD4 T lymphocytes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00002030-200305020-00007

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 170

Metadata

Authors
van Leeuwen, R., Katlama, C., Murphy, R. L., Squires, K., Gatell, J., Horban, A., Clotet, B., Staszewski, S., van Eeden, A., Clumeck, N., Moroni, M., Pavia, A. T., Schmidt, R. E., Gonzalez-Lahoz, J., Montaner, J., Antunes, F., Gulick, R., Bánhegyi, D., van der Valk, M., Reiss, P., van Weert, L., van Leth, F., Johnson, V. A., Sommadossi, J.-P., & Lange, J. M.
Venue
AIDS
Published
2003-05
Volume
17
Issue
7
Pages
987-999
ISSN
0269-9370 (ISSN-L)
OpenAlex
W2145897295
Cited by
170
References
2
FWCI
18.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. https://app.cochat.ai/papers/10.1097/00002030-200305020-00007
The paper
van Leeuwen, R., Katlama, C., Murphy, R. L., Squires, K., Gatell, J., Horban, A., Clotet, B., Staszewski, S., van Eeden, A., Clumeck, N., Moroni, M., Pavia, A. T., Schmidt, R. E., Gonzalez-Lahoz, J., Montaner, J., Antunes, F., Gulick, R., Bánhegyi, D., van der Valk, M., . . . Lange, J. M. (2003). A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. https://doi.org/10.1097/00002030-200305020-00007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.